Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents
Zurletrectinib 是一种新一代 TRK 抑制剂,对具有靶向耐药性的 NTRK 融合阳性肿瘤具有强大的颅内活性。
期刊:British Journal of Cancer
影响因子:6.8
doi:10.1038/s41416-024-02760-1
Roa, Paola; Foglizzo, Valentina; Harada, Guilherme; Repetto, Matteo; Kulick, Amanda; de Stanchina, Elisa; de Marchena, Michelle; Auwardt, Supipi; Sayed Ahmed, Shaza; Bremer, Nicole Virginia; Yang, Soo-Ryum; Feng, Yangbo; Zhou, Chao; Kong, Norman; Liang, Ruixia; Xu, Haipeng; Zhang, Bin; Bardelli, Alberto; Toska, Eneda; Ventura, Andrea; Drilon, Alexander; Cocco, Emiliano